Drug Database
Back to search

Poland· PL-100504822

Piasky

A crovalimab product containing crovalimabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC L04AJ07

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPiaskyATCL04AJ07REGISTER NO.PL-100504822PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about crovalimabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Crovalimab is registered in 11 of 19 countries.

Countries holding a registration under ATC L04AJ07 (crovalimab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search crovalimab products by name

Crovalimab · ATC L04AJ07

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Crovalimabum
Manufacturer
Roche Registration GmbH
Country
Poland (PL)
ATC code
L04AJ07
ATC class
Crovalimab
Defined daily dose
24.3 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    07613326085861

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Crovalimab in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All crovalimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Piasky
  • Liechtenstein · Piasky
  • Norway · Piasky

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ce741b97-0033-4d83-b4a3-91167822b9e1
GET /v1/drugs/ce741b97-0033-4d83-b4a3-91167822b9e1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań / do infuzji",
  "source": "urpl",
  "strength": "340 mg",
  "packaging": "07613326085861 ¦ Rpz ¦ EU/1/24/1848/001 ¦ 157880\n1 fiol.",
  "substance": "Crovalimabum 340 mg",
  "common_name": "Crovalimabum",
  "pl_product_id": "100504822",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about crovalimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console